Kidney Transplant Rejection Market to Grow at a Substantial Growth Rate During the Forecast Period (2019-32) | Key Players- Novartis, Medeor Therapeutics, Talaris Therapeutics, CSL Behring, and others

June 29 03:12 2022
Kidney Transplant Rejection Market to Grow at a Substantial Growth Rate During the Forecast Period (2019-32) | Key Players- Novartis, Medeor Therapeutics, Talaris Therapeutics, CSL Behring, and others
Delveinsight Business Research LLP
DelveInsight’s “Kidney Transplant Rejection Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Kidney Transplant Rejection Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Kidney Transplant Rejection market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Kidney Transplant Rejection: An Overview

Kidney transplant rejection is an immunological response that leads to inflammation with specific pathological changes in the allograft due to the recipient’s immune system recognizing the non-self (foreign) antigen in the allograft, with or without dysfunction of the allograft.

Both innate and adaptive immune systems play a significant role in rejection, but the T lymphocytes are the principal cells that recognize the allograft. There are other costimulatory molecules, and cytokines also that play a major role in this reaction. 

Most patients who have acute rejection episodes are asymptomatic and have abnormal allograft dysfunction, as evidenced by the routine blood workups; when there is a sudden rise of serum creatinine to more than 25% of the baseline value, the clinicians should suspect allograft rejection. 

Kidney Transplant Rejection Market Key Facts

  • A recent analysis of more than 250,000 North American renal transplant recipients showed that despite modest improvements in long-term graft survival between 1989 and 2005, and improvements in graft half-life in the past decade for both living and deceased donor transplants, high attrition rates persist that stubbornly limit recent progress (Djamali et al., 2014).

  • According to DelveInsight’s analysis, there is no gender-based difference; however, older individuals have a higher incidence of kidney transplant rejection than young individuals.

  • In a study of 22,730 UK kidney recipients, 5,389 (23.7%) grafts failed within a median follow-up of 5 years. The two most frequent causes were death with a functioning graft (40.8%) and alloimmune pathology (25.0%) (Burton et al., 2018).

Kidney Transplant Rejection Market

As per DelveInsight, the Kidney Transplant Rejection market size shall grow during the forecast period owing to increased research and development (R&D) activities, a rise in the patient pool and the launch of the potential pipeline products.

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Kidney Transplant Rejection market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the Kidney Transplant Rejection market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.

Kidney Transplant Rejection Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.

Kidney Transplant Rejection Epidemiology Segmentation

  • Total Cases of Kidney Transplant

  • Type-specific Cases of Kidney Transplant Rejection

  • Incident Cases of Kidney Transplant Rejection

  • Treatable Cases of Kidney Transplant Rejection

Kidney Transplant Rejection Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Kidney Transplant Rejection market or expected to get launched during the study period. The analysis covers Kidney Transplant Rejection market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Kidney Transplant Rejection Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Request for Sample PDF Report –

Kidney Transplant Rejection Therapeutics Analysis

The Kidney Transplant Rejection market size is expected to change in the coming years owing to the increased incidence of end-stage renal disease for which kidney transplant remains to be the best therapy in terms of cost-effectiveness and advancement in immunosuppressive strategies and surgery.

Some of the key companies in the Kidney Transplant Rejection Market include:

  • Novartis

  • Medeor Therapeutics

  • Talaris Therapeutics

  • CSL Behring

And others

Kidney Transplant Rejection Therapies covered in the report include:

  • CFZ533

  • MDR-101

  • MDR-102

  • FCR001

  • Clazakizumab

And many more.

Get More Detailed Insights Into the Emerging Therapies & Key Companies –

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Kidney Transplant Rejection Competitive Intelligence Analysis

4. Kidney Transplant Rejection Market Overview at a Glance

5. Kidney Transplant Rejection Disease Background and Overview

6. Kidney Transplant Rejection Patient Journey

7. Kidney Transplant Rejection Epidemiology and Patient Population

8. Kidney Transplant Rejection Treatment Algorithm, Current Treatment, and Medical Practices

9. Kidney Transplant Rejection Unmet Needs

10. Key Endpoints of Kidney Transplant Rejection Treatment

11. Kidney Transplant Rejection Marketed Products

12. Kidney Transplant Rejection Emerging Therapies

13. Kidney Transplant Rejection Seven Major Market Analysis

14. Attribute Analysis

15. Kidney Transplant Rejection Market Outlook (7 major markets)

16. Kidney Transplant Rejection Access and Reimbursement Overview

17. KOL Views on the Kidney Transplant Rejection Market.

18. Kidney Transplant Rejection Market Drivers

19. Kidney Transplant Rejection Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report –

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.


Other Latest Healthcare Report by DelveInsight

Erythropoietic Protoporphyria Market

“Erythropoietic Protoporphyria Market” report delivers an in-depth understanding of the historical and forecasted epidemiology, Erythropoietic Protoporphyria market trends in 7MM as well as the key companies and the emerging therapies in the therapeutics market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States